Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout

Authors


Dr Ai Tran, Sir Charles Gairdner Hospital, Rheumatology, Hospital Avenue, Nedlands, Perth, Western Australia 6009, Australia. Email: aptran7@msn.com

Abstract

Since the discovery of the inflammasome, interleukin 1 production has been found to be integral in the pathophysiology of gout. Interleukin 1 inhibition by Anakinra has been shown to effective for the treatment of gout. We report three cases of resistant chronic tophaceous gout who responded to anakinra subcutaneous injections on an intermittent basis.

Ancillary